Your browser is no longer supported. Please, upgrade your browser.
TLSA [NASD]
Tiziana Life Sciences PLC
Index- P/E- EPS (ttm)-0.23 Insider Own- Shs Outstand150.22M Perf Week-6.07%
Market Cap17.07M Forward P/E- EPS next Y- Insider Trans- Shs Float19.46M Perf Month-16.22%
Income-39.70M PEG- EPS next Q- Inst Own7.20% Short Float0.35% Perf Quarter-42.50%
Sales-3.60M P/S- EPS this Y-124.80% Inst Trans- Short Ratio0.50 Perf Half Y-52.19%
Book/sh0.32 P/B2.75 EPS next Y- ROA-109.40% Target Price7.75 Perf Year-72.25%
Cash/sh2.73 P/C0.32 EPS next 5Y- ROE-141.90% 52W Range0.78 - 5.29 Perf YTD-8.36%
Dividend- P/FCF- EPS past 5Y-44.80% ROI- 52W High-83.37% Beta-
Dividend %- Quick Ratio6.50 Sales past 5Y- Gross Margin- 52W Low12.78% ATR0.10
Employees11 Current Ratio6.50 Sales Q/Q- Oper. Margin- RSI (14)38.46 Volatility9.30% 10.61%
OptionableYes Debt/Eq0.02 EPS Q/Q-215.60% Profit Margin- Rel Volume1.21 Prev Close0.83
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume136.52K Price0.88
Recom2.00 SMA20-7.40% SMA50-23.87% SMA200-51.86% Volume162,982 Change5.99%
Dec-22-20Initiated B. Riley Securities Buy $8
Dec-17-18Initiated Laidlaw Buy
Jan-13-22 07:00AM  
Jan-11-22 04:12AM  
Jan-10-22 07:00AM  
Jan-06-22 04:15PM  
Oct-21-21 02:00AM  
Oct-20-21 09:40AM  
02:00AM  
Oct-19-21 09:26AM  
Oct-07-21 06:10AM  
Sep-28-21 04:19AM  
Sep-27-21 12:39PM  
Sep-24-21 12:51PM  
Sep-20-21 07:45AM  
Sep-07-21 02:00AM  
Sep-03-21 10:27AM  
02:00AM  
Sep-02-21 09:42AM  
06:02AM  
02:00AM  
02:00AM  
Aug-20-21 02:00AM  
Aug-17-21 02:00AM  
Aug-16-21 04:36PM  
01:14PM  
Aug-04-21 01:56AM  
Jul-08-21 07:59AM  
Jul-02-21 07:58AM  
Jul-01-21 05:40AM  
Jun-30-21 06:47AM  
Jun-25-21 06:15AM  
Jun-23-21 02:00AM  
Jun-21-21 02:00AM  
Jun-17-21 02:00AM  
Jun-02-21 02:00AM  
May-27-21 07:14AM  
May-26-21 06:37AM  
02:00AM  
May-25-21 06:16AM  
02:00AM  
May-07-21 02:00AM  
May-05-21 02:00AM  
Apr-30-21 12:00AM  
Apr-27-21 02:00AM  
Apr-14-21 05:00AM  
Apr-13-21 07:00AM  
Apr-12-21 06:07AM  
Mar-30-21 08:00AM  
07:35AM  
05:01AM  
02:00AM  
Mar-29-21 08:30AM  
02:00AM  
Mar-17-21 04:03PM  
Feb-26-21 02:00AM  
Feb-18-21 07:00AM  
Feb-16-21 10:02AM  
Feb-05-21 02:00AM  
Feb-03-21 10:11AM  
02:00AM  
Feb-02-21 05:55AM  
04:57AM  
04:15AM  
02:00AM  
Jan-27-21 02:00AM  
Jan-20-21 06:31AM  
02:00AM  
Jan-13-21 02:00AM  
Jan-11-21 12:08PM  
09:48AM  
Jan-04-21 02:00AM  
Dec-18-20 06:38AM  
Dec-17-20 10:04AM  
Dec-14-20 10:28PM  
Dec-01-20 02:00AM  
Nov-18-20 10:16AM  
Nov-11-20 02:00AM  
Nov-02-20 03:31AM  
02:00AM  
Oct-27-20 12:00PM  
Oct-22-20 07:28AM  
Oct-02-20 07:00AM  
Sep-25-20 02:00AM  
Sep-21-20 09:51AM  
Sep-17-20 02:00AM  
Sep-16-20 10:10AM  
06:00AM  
02:00AM  
Aug-28-20 05:30AM  
Aug-27-20 02:00AM  
Aug-24-20 08:42AM  
03:14AM  
02:00AM  
Aug-21-20 02:00AM  
Aug-20-20 02:00AM  
Aug-18-20 06:08AM  
02:00AM  
Aug-11-20 04:00AM  
Aug-06-20 03:57PM  
Aug-05-20 11:00AM  
Aug-04-20 02:00AM  
Tiziana Life Sciences plc, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology, inflammation, and infectious diseases. Its lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. The company is also developing Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat COVID-19 patients. It has a collaboration agreement with FHI Clinical to conduct a Phase 2 clinical trials for treating hospitalized severe COVID-19 patients with intranasal foralumab. The company was incorporated in 1998 and is based in London, the United Kingdom.